Key result
Catheter-directed thrombolysis is linked to ~60% lower mortality in ICU patients with submassive PE.
Why the study?
Catheter-directed thrombolysis effectively reduces right ventricle strain in submassive pulmonary embolism, but its impact on clinical outcomes compared with standard anticoagulation remained unclear.
Does catheter-directed thrombolysis reduce all-cause mortality compared to standard systemic anticoagulation in patients admitted to the ICU with acute submassive pulmonary embolism?
Cohort (n=339)
Yes
Does catheter-directed thrombolysis reduce all-cause mortality compared to standard systemic anticoagulation in patients admitted to the ICU with acute submassive pulmonary embolism?
In this retrospective propensity-matched cohort of ICU patients with acute submassive pulmonary embolism, catheter-directed thrombolysis was associated with lower 30-day and 1-year mortality and shorter hospital stay compared to standard anticoagulation, without increasing bleeding rates.
Answers are grounded in this paper and cite their sources.
May support catheter-directed thrombolysis evaluation in ICU submassive PE; leaves open randomized confirmation of mortality benefit.
BACKGROUND: Catheter-directed thrombolysis (CDL) is increasingly being used for the treatment of submassive and massive pulmonary embolism. Although this therapy has been shown to be effective at reducing right ventricle strain, the impact on clinical outcomes remains unclear. We therefore aimed to evaluate the outcomes of CDL compared to standard anticoagulation for submassive pulmonary embolism patients in a large cohort. METHODS: We conducted a retrospective observational study of consecutive patients with a primary diagnosis of submassive pulmonary embolism admitted to an intensive care unit within our health system between June 2014 and April 2016. We compared the outcome of patients treated with systemic anticoagulation (medical therapy) vs. catheter-based delivery of tissue plasminogen activator (tPA) (CDL). CDL patients were matched with medical therapy controls using a propensity-score matching algorithm based on the components of the simplified pulmonary embolism severity index (sPESI) score. RESULTS: Unadjusted mortality rates were 3.0% for CDL vs. 10.4% for medical therapy at 30 days and 8.1% for CDL vs. 22.9% for medical therapy at 1 year. In the propensity-score matched cohort, mortality rates were 3.1% for CDL vs. 6.1% for medical therapy at 30 days and 8.2% for CDL vs. 18.2% for medical therapy at 1 year. Length of stay was significantly shorter in the CDL group. The index admission bleeding and transfusion rates were not increased in the CDL group. CONCLUSIONS: In patients presenting with acute submassive pulmonary embolism who are admitted to an intensive care unit, the group treated with CDL experienced reduced mortality at 30 days and 1 year when compared to medical therapy without increase in bleeding. Further randomized studies are required to confirm these findings.
No takes yet. Share an insight, caveat, or question.
D’Auria et al. (2019) conducted a cohort in Acute submassive pulmonary embolism (n=339). Catheter-directed thrombolysis (CDL) with tissue plasminogen activator (tPA) vs. Standard medical therapy (systemic anticoagulation via IV or oral agents) was evaluated on All-cause mortality in the propensity-score matched cohort (1-year rate and overall hazard ratio) (HR 0.4, 95% CI 0.169-0.792, p=0.011). Catheter-directed thrombolysis was associated with lower all-cause mortality compared to standard medical therapy in ICU patients with submassive PE.
Synapse has enriched 10 related papers. Consider them for comparative context: